Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gain Therapeutics, Inc.

1.74
+0.01000.58%
Post-market: 1.750.0100+0.57%18:38 EDT
Volume:111.68K
Turnover:192.62K
Market Cap:51.43M
PE:-2.13
High:1.81
Open:1.77
Low:1.66
Close:1.73
Loading ...

Gain Therapeutics Inc. to Present at H.C. Wainwright Neuro Perspectives Hybrid Conference and BIO 2025

Reuters
·
10 Jun

Gain Therapeutics Inc. Announces Oral Presentation at GBA1 Meeting 2025 in Montreal

Reuters
·
29 May

Gain Therapeutics Announces Oral Presentation at 2Nd Gba1 Meeting

THOMSON REUTERS
·
29 May

Gain Therapeutics Files $100 Million Mixed Shelf

MT Newswires Live
·
29 May

Gain Therapeutics files $100M mixed securities shelf

TIPRANKS
·
29 May

Gain Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
19 May

Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Reviva Pharmaceuticals Holdings (RVPH)

TIPRANKS
·
18 May

Gain Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

THOMSON REUTERS
·
14 May

Gain Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
09 May

Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating

TIPRANKS
·
01 May

Gain Therapeutics Inc. to Present and Participate at The Citizens Life Sciences Conference

Reuters
·
01 May

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

GlobeNewswire
·
01 May

BRIEF-Gain Therapeutics Announces Oral Poster Presentation

Reuters
·
30 Apr

Gain Therapeutics Announces Oral Poster Presentation at Iaprd 2025 30TH World Congress on Parkinson’s Disease and Related Disorders

THOMSON REUTERS
·
30 Apr

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

GlobeNewswire
·
30 Apr

Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

Insider Monkey
·
12 Apr

Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Justify Buy Rating

TIPRANKS
·
12 Apr

Gain Therapeutics Unveils New Parkinson’s Treatment Data

TIPRANKS
·
11 Apr

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

GlobeNewswire
·
10 Apr